Skip to content
Try Mental Wellness – Lifestyle
Author:
Edgewise Therapeutics, Inc.
/C O R R E C T I O N – Edgewise Therapeutics/
November 9, 2026
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
November 9, 2026
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
November 5, 2026
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
November 4, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
November 2, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
October 8, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
October 1, 2026
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
September 22, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
September 2, 2026
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
August 24, 2026
1
2
Next Page
→